New pill combo aims to fight Hard-to-Treat breast cancer

NCT ID NCT07557004

Ongoing Disease control Sponsor: Nanjing Sanhome Pharmaceutical, Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a new oral drug, SH3765, combined with the injectable hormone therapy fulvestrant in 30 women with advanced HR+/HER2- breast cancer that has worsened after prior treatment. The main goals are to check safety, find the best dose, and see if the combination shrinks tumors. Results will guide whether larger studies are warranted.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SH3765 tablets and fulvestrant injection
What this could lead to: If it works, this could point toward a new combination treatment for advanced HR+/HER2- breast cancer that has stopped responding to prior hormone therapy.
What could go wrong: This is a very early Phase 1 trial with only 30 participants, so it is primarily testing safety and dosing. It is too small to prove effectiveness, and the drug may not work or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HR+, HER2-, ADVANCED BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HR+, HER2-, ADVANCED BREAST CANCER

Contacts and locations

Locations

The First Affiliated Hospital Of USTC Anhui Provincial Hospital

Hefei, Anhui, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.